<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4CE7F120-76BD-4928-A399-F406EB268C89"><gtr:id>4CE7F120-76BD-4928-A399-F406EB268C89</gtr:id><gtr:name>Procarta Biosystems Limited</gtr:name><gtr:address><gtr:line1>Norwich Bioincubator
Colney Lane</gtr:line1><gtr:city>Norwich</gtr:city><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4CE7F120-76BD-4928-A399-F406EB268C89" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>4CE7F120-76BD-4928-A399-F406EB268C89</gtr:id><gtr:name>Procarta Biosystems Limited</gtr:name><gtr:address><gtr:line1>Norwich Bioincubator
Colney Lane</gtr:line1><gtr:city>Norwich</gtr:city><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24975.0</gtr:offerGrant><gtr:projectCost>33300.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C20A6D22-844D-4795-BAF5-A8FEFAD2DFDF"><gtr:id>C20A6D22-844D-4795-BAF5-A8FEFAD2DFDF</gtr:id><gtr:firstName>Kostas</gtr:firstName><gtr:surname>Hatzixanthis</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131124"><gtr:id>24E25A75-863C-4065-B7DB-716DB43CEB4E</gtr:id><gtr:title>Process development and manufacture of nanoparticulate - based antibacterials</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131124</gtr:grantReference><gtr:abstractText>Procarta is developing a lasting solution to the treatment of bacterial infections using a proprietary technology platform based on nanoparticulate oligonucleotide therapeutics.
This project will enable better understanding of how to manufacture the delivery nanoparticles, define and fix key QC parameters, leading to a production process for scale up. This manufacturing process will become a strong basis for developing a range of antibacterials able to combat existing and emerging nosocomial infections (MRSA and Clostridium difficile superbugs) as well as the emerging threat of Gram negative infections.</gtr:abstractText><gtr:fund><gtr:end>2013-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24975</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131124</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>